Abstract
To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox(®)), and percutaneous tibial nerve stimulation (PTNS). A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best-worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to -1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey's multiple comparisons test. The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagno...Continue Reading
References
Apr 16, 2003·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A S Arunkalaivanan, J W Barrington
Jul 5, 2005·Urology·Heinrich Schulte-BauklohHelmut H Knispel
Oct 20, 2006·European Urology·Debra E IrwinPaul Abrams
May 16, 2009·Journal of Neurology·F Reed JohnsonJ Theodore Phillips
Jul 16, 2009·British Journal of Cancer·K M BeusterienA R Levy
Nov 26, 2009·International Urogynecology Journal·Bernard T HaylenGabriel N Schaer
May 21, 2010·Health and Quality of Life Outcomes·Kathleen M BeusterienSteve Bramham-Jones
Jun 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Terry N Flynn
Jul 20, 2010·Urologia Internationalis·Ricarda M BauerFlorian May
Dec 21, 2010·The Journal of Urology·Randall K LeongStefan G De Wachter
Jan 15, 2011·BJU International·Debra E IrwinPaul Abrams
Jan 21, 2011·The Journal of Urology·Carol L LinkJohn B McKinlay
Oct 15, 2011·The Patient·John F P BridgesAxel Mühlbacher
Jan 26, 2012·International Urogynecology Journal·Linda BrubakerKarl-Dietrich Sievert
Feb 5, 2013·Urology·Una J LeeJennifer T Anger
Jul 28, 2013·Expert Opinion on Pharmacotherapy·Dean S EltermanJack Barkin
Mar 19, 2014·International Urogynecology Journal·Pooja Balchandra, Lynne Rogerson
May 24, 2014·Clinical Therapeutics·Holly L PeayJohn F P Bridges
Dec 1, 2013·Arab Journal of Urology·Ahmed S El-Azab, Ahmed M Moeen
Citations
Jan 9, 2016·Health Economics Review·Axel C MühlbacherF Reed Johnson
Apr 27, 2017·Neurourology and Urodynamics·Apostolos ApostolidisRoger Dmochowski
Feb 7, 2019·International Urology and Nephrology·Bulent CetinelMurat Dincer
Dec 1, 2018·Neurourology and Urodynamics·Le Mai TuKarel Everaert
Feb 27, 2016·F1000Research·Karen M Wallace, Marcus J Drake
Aug 14, 2020·British Journal of Nursing : BJN·Nicholas Fletcher
Nov 28, 2016·International Urogynecology Journal·Pawel MiotlaTomasz Rechberger
Jul 13, 2016·PharmacoEconomics·Kei Long CheungMickael Hiligsmann
Apr 11, 2018·World Journal of Urology·Pierre-Adrien LerouxJulie Carrouget
Oct 15, 2019·International Neurourology Journal·M A ElbasetA A Shokeir
May 27, 2020·Current Opinion in Urology·Manon Te DorsthorstJohn Heesakkers
Oct 13, 2018·Der Urologe. Ausg. A·Arndt van Ophoven
Apr 4, 2019·Archives of Gynecology and Obstetrics·Matthias OelkeChristl Reisenauer
Nov 22, 2020·International Journal of Clinical Practice·Arun SahaiDudley Robinson
Nov 23, 2020·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·X Gamé, V Phé
Jul 2, 2021·Clinical Therapeutics·Tara A LavelleJohn F P Bridges